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Synthesis, Characterization and 
Immunological Evaluation of 
Self-Adjuvanting Group A 
Streptococcal Vaccine 
Candidates Bearing Various 
Lipidic Adjuvanting Moieties 
Vincent Fagan,[a] Waleed M. Hussein, [a] Mei Su, [a] 
Ashwini K. Gidda, [a] Michael R. Batzloff, [b]  
Michael F. Good, [b]  Istvan Toth, [a] [c] [d] and Pavla 
Simerska *[a] 
Abstract: Four group A streptococcal glyco-lipopeptide vaccine 
candidates were prepared and characterized, each possessing 
different lipidic adjuvanting moieties. The immunogenicity of the 
compounds was evaluated by macrophage and dendritic cell uptake 
studies and by in vivo quantification of systemic IgG antibody using 
ELISA. Three of the four vaccine candidates showed a significant 
induction of IgG response compared to a negative control. 
Introduction 
Adjuvants are important immuno-stimulatory components of 
vaccines, which significantly boost immune responses towards 
antigens. Adjuvant development has progressed slowly in the 
past decades, with aluminum salts being the most common 
adjuvants in use.[1] Recently, research efforts have focused on the 
development of adjuvants that activate pattern recognition 
receptors (PRRs) found on immune cells. PRRs recognize 
conserved pathogen-associated molecular patterns. This leads to 
the activation of cells of the innate and adaptive immune system, 
resulting in significantly enhanced immune responses.[2] By 
preparing agonists for a particular type of PRR (e.g. Toll-Like 
Receptor (TLR)), an appropriate immune response can be 
induced for each type of pathogen.[3] TLR2 is present on cells of 
the innate and adaptive immune system. It recognizes conserved 
lipidic structural components of bacteria, fungi and viruses, and 
plays a key role in the body’s defenses, particularly against gram 
positive bacteria.[4] Research efforts within our group have shown 
that a short sequence of synthetic lipo-amino acids (LAAs), 
referred to as the Lipid Core Peptide (LCP), can bind to TLR2, 
which results in increased immune responses to otherwise poorly 
immunogenic peptide antigens.[5] The LCP has been combined 
with multiple copies of B cell epitopes from Streptoccus pyogenes 
in an effort to develop a fully synthetic self-adjuvanting vaccine 
against this pathogen.[5-9] S. pyogenes is a Gram-positive 
bacterium that affects the skin and upper respiratory tract, and 
causes a range of health issues that are collectively referred to as 
group A streptococcal (GAS) infections.[10] The most severe GAS 
related problems are post-streptococcal rheumatic fever and 
rheumatic heart disease, which account for over half a million 
deaths annually.[11] Carbohydrates have been shown to be 
important in vaccine development and peptide delivery.[12] 
Recently, we reported a new synthetic methodology for the 
preparation of large, multi-component carbohydrate core vaccine 
candidates against GAS.[13] First, glyco-lipopeptides were 
prepared, which contained a lipidic adjuvanting sequence, 
followed by a known promiscuous T-helper epitope (PADRE), and 
terminated with a tetra-propargyl glucose (TPGlc) moiety. The 
lipidic adjuvanting sequence contained three lipidated lysine 
residues and was a simplified version of the LCP system. This 
adjuvanting sequence was employed for the purpose of 
developing the synthetic methodology. The final vaccine 
candidate (J8-Glc-PADRE-lipid) was constructed by employing 
the Huisgen copper-catalyzed azide-alkyne cycloaddition “click” 
reaction (CuAAC)[14] to couple four copies of a GAS B cell epitope, 
known as J8.[13] 
The J8 B cell epitope (sequence; 
QAEDKVKQSREAKKQVEKALKQLEDKVQ) was identified from 
the conserved C-terminal region of the M protein (a cell surface 
protein and a major virulence factor) of S. pyogenes.[15] It was 
shown to elicit systemic IgG antibodies, which were capable of 
opsonizing the GAS pathogen and inducing protective immunity 
against GAS. The J8 epitope has been employed previously in a 
number of studies.[8, 16-19] 
Although B cells may be activated via a number of T cell-
independent routes, the T cell-dependent activation of B cells can 
lead to a stronger, more long-term immune response.[2] The 
PADRE T-helper epitope (Pan DR Epitope; KFVAAWTLKAA) has 
been shown to be recognized by a high percentage of the human 
population, and is thus referred to as a promiscuous T-helper 
epitope.[20] Incorporation of this epitope should allow for T cell-
dependent activation of B cells, and lead to a stronger and longer 
lasting immune response. 
The synthetic approach used to synthesize the J8-Glc-PADRE-
lipid gave vaccine candidates of increased complexity compared 
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to those prepared previously,[8] yet purification of the final vaccine 
candidates was more readily achieved.[13] In the current study, a 
similar synthetic approach was employed to prepare four novel 
vaccine candidates, with each containing a different lipidic 
adjuvanting moiety.  
The uptake of antigens by professional antigen-presenting cells is 
crucial for the initiation of a fully developed, long-term immune 
response.[21] Dendritic cell (DC) and macrophage uptake assays 
were performed to determine which of the vaccine candidates 
could be taken up most efficiently. Dynamic light scattering (DLS) 
and transmission electron microscopy (TEM) were employed to 
determine particle size of the vaccine candidates. The M protein 
of GAS possesses an α-helical secondary structure, therefore, 
circular dichroism (CD) was employed to assess the secondary 
structure of the vaccine candidates. The immunogenicity of the 
four vaccine candidates was evaluated by carrying out enzyme-
linked immunosorbent assays (ELISAs) of blood taken from 
immunized mice. 
Results and Discussion 
Figure 1. Novel vaccine candidates 1a-d containing different lipidic adjuvanting 
moieties. 
Design 
In order to efficiently prepare the target set of compounds (1a-d, 
Figure 1), the methodology reported previously[13] was further 
developed so that branched systems could be prepared. Four 
vaccine candidates were synthesized, each containing the 
PADRE T-helper epitope and four copies of the J8 B cell epitope 
conjugated to the TPGlc scaffold. However, each contained a 
different lipidic adjuvanting moiety (Figure 1). 
Compound 1a contained the LCP adjuvanting system. Vaccine 
candidates have previously been prepared containing this lipidic 
sequence, as well as, multiple copies of the J8 epitope on a 
polylysine scaffold.[22] Mice immunized with these vaccine 
candidates gave high J8-specific antibody titers after the final 
boost. The induced antibodies were capable of opsonizing a 
number of different GAS strains[18] and immunized mice displayed 
protective immunity when challenged in vivo with GAS.[17] 
Following structure-activity relationship studies about the number 
of LAAs and their chain length, the LCP adjuvant was developed 
into the lipidic adjuvanting sequence in compound 1b (Figure 1), 
herein referred to as Lipid Core Peptide 2 (LCP2).[6, 23]  
 
Immunization with constructs containing the LCP2 adjuvanting 
sequence resulted in antibody titers that were comparable to that 
of constructs containing the LCP lipidic adjuvant.[6] 
The lipidic adjuvant contained in 1c (LLCP; Lysine Lipid Core 
Peptide) was recently reported as a simplified version of the 
LCP.[13] This adjuvanting system was used for the purpose of 
developing a novel synthetic methodology and, until now, has not 
been immunologically evaluated. The adjuvanting properties of 
similar systems containing palmitoyl lysines have been reported 
by Huang et al., but notable immunological responses could only 
be achieved by incorporating the constructs into liposomes or oil-
emulsions.[24] 
The final compound, 1d, contained a lipidic adjuvant that bears 
close structural resemblance to the well-known 2,3-dipalmitoyl-S-
glycerylcysteine (Pam2Cys) lipidic adjuvanting moiety (Figure 
2).[25-27]  
The dipalmitoyl serine (DPS) adjuvant can be easily synthesized 
as an enantiomerically pure moiety, using standard solid phase 
peptide synthesis (SPPS), from readily available starting 
materials. Recently, we demonstrated that the DPS adjuvanting 
moiety showed strong binding affinity to the extracellular domain 
of the TLR2.[28]  
Figure 2. Pam2Cys as it appears in the TLR2 active site[29] and the DiPalmitoyl 
Serine (DPS) adjuvant in a similar conformation. 
Synthesis 
The synthesis of the target compounds began by growing a 
peptide sequence consisting of two lysine residues followed by         
the PADRE T-helper epitope[20] and an additional two lysine 
residues. The side chain of the terminal lysine amino acid was 
protected with an ivDde group (Scheme 1). 
The ivDde group can be selectively removed using dilute 
hydrazine and is commonly employed when synthesizing 
branched peptides.[30] Unless otherwise stated, amino acids were 
coupled using standard microwave assisted Fmoc SPPS and 
commercially available Fmoc protected amino acids (see 
Experimental section). The PADRE T-helper epitope was flanked 
by additional lysine residues in order to increase the hydrophilicity 
of glyco-lipopeptides, thus improving their solubility. The TPGlc 
carbohydrate building block was prepared using a previously 
reported synthesis[13] and was coupled to the N-terminus of the 
peptide. Almost quantitative coupling was achieved when the 
TPGlc and diisopropyl ethyl amine (DIPEA) were added to the 
resin with stirring, followed by the addition of the HBTU coupling 
reagent. The ivDde protecting group was then selectively 
removed from the lysine side chain using the standard conditions 
of 2% hydrazine in DMF.[30] A standard Fmoc protected lysine was 
coupled and the resin bound glycopeptide 2 was dried under 
vacuum. The glycopeptide 2 was divided into four equal portions 
so that all four target compounds could be synthesized from one 
glycopeptide. This approach is more efficient compared to the 
non-branched approach reported previously,[13] since 
glycopeptide 2, consisting of the T-helper epitope and the TPGlc 
carbohydrate scaffold, needed to be synthesized only once. 
Similarly, by removing the ivDde group prior to dividing the resin, 
this relatively lengthy deprotection needed to be performed only 
once. After dividing the resin, the lysine Fmoc protecting group 
was removed using piperidine, and the lipidic adjuvanting moiety 
could be incorporated (Scheme 2). 
The lipidic adjuvanting moieties of glyco-lipopeptides 3a and 3b 
have been prepared previously using Boc[6, 8] or Dde[31] protected 
synthetic LAAs. In this case, Dde protected LAAs were employed 
(Dde-C12-OH, Dde-C16-OH) and prepared according to the 
procedure of Ross et al.[32] The lipidated lysine amino acid (Fmoc-
Scheme 1. Synthesis of the resin bound glycopeptide 2. 
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K(C12)-OH) was synthesized according to the procedure reported 
by Fagan et al.,[13] and was used to prepare the lipidic sequence 
of glyco-lipopeptide 3c by standard Fmoc SPPS. 
The DPS lipidic adjuvanting moiety of glyco-lipopeptide 3d was 
prepared by coupling two standard Fmoc protected serine amino 
acids (Fmoc-Ser(tBu)-OH) (Scheme 3). These amino acids were 
incorporated so that the adjuvanting sequence of 3d was 
analogous to that of 3b. A third Fmoc protected serine was 
coupled; however, its side chain hydroxyl group was unprotected. 
To avoid unwanted ester formation the amino acid (Fmoc-Ser-
OH) and DIPEA were added with stirring to the resin, followed by 
the addition of HBTU. Following Fmoc removal, the terminal 
amine and the unprotected side chain hydroxyl group were 
simultaneously lipidated using a mixture containing palmitic acid, 
diisopropyl carbodiimide (DIC), and dimethylaminopyridine 
(DMAP). The protocol completely avoids solution phase synthesis 
of building blocks and leads to an enantiomerically pure product. 
Each glyco-lipopeptide (3a-d) was cleaved from the resin using 
standard Fmoc SPPS cleavage conditions. Following cleavage 
from the resin, the glyco-lipopeptides were used without 
purification in the final step. The CuAAC[14] reaction was 
employed to conjugate four copies of the J8 B cell epitope to each 
of the glyco-lipopeptides 3a-d (Scheme 4). The azide 
functionalized J8 B cell epitope (N3-J8) was prepared using 
standard Fmoc SPPS, as described previously.[13] The 
cycloadditon reaction between the crude glyco-lipopeptides 3a-d 
and N3-J8 was performed according to the procedure reported by 
Urbani et al.[33] As the reaction proceeded, a blue/green color 
appeared. The reaction was deemed to be complete when the 
color was first distinguishable (approx. 1-2 h), at which point the 
reaction was cooled in a bath of dry ice and filtered to remove the 
copper wire. The target vaccine candidates 1a-d were purified by 
preparative reverse phase (RP) HPLC using a C4 column in 12-
32% yield, and were characterized by mass spectrometry and 
analytical RP-HPLC (see supplementary materials). 
Figure 3. Uptake of 1a-d by mouse splenocyte-derived DCs and macrophages 
presented as the percentage of cells positive for the test compound (labeled 
with Dil) and CD11c-A660 or F4/80-APC-Cy7. Dextran and Phosphate-Buffered 
Saline (PBS) were used for positive and negative controls, respectively. The 
bars represent the mean ± standard deviation of three experiments. 
The particle size of the four vaccine candidates was determined 
by DLS and TEM. The compounds were dissolved in phosphate 
buffer saline (PBS), and added to glow discharged carbon coated 
200 mesh grids (for TEM). Each of the four vaccine candidates 
possessed particle sizes of approximately 9 to 11 nm in diameter 
(see Supporting Information). These vaccine particle sizes are 
similar to the effective peptide-based vaccine sizes reported 
earlier.[34] 
 
Dendritic Cell and Macrophage Uptake Assay 
For a vaccine candidate to be effective, it must be efficiently taken 
up by antigen presenting cells (particularly DCs).[21] Therefore, DC 
and macrophage uptake assays were performed according to the 
literature.[35-36] The vaccine candidates 1a-d were labeled with Dil 
(1,1’-dioctadecyl-3,3,3’,3’-tetramethylindocarbocyanine 
perchlorate) and incubated with DCs and macrophages, which 
were derived from mouse splenocytes. Following incubation with 
Dil labeled 1a-d, the cells were labelled with CD11c-A660 and 
F4/80-APC-Cy7 antibodies for DCs and macrophages, 
respectively, and their fluorescence was measured by flow 
cytometry. Uptake was calculated as the percentage of cells that 
were double positive for Dil-labeled compound and CD11c-A660 
or F4/80-APC-Cy7 (Figure 3). 
 
The results indicated that uptake was consistently more efficient 
in DCs compared to macrophages. Although there was no 
statistical difference between each of the vaccine candidates, at 
lower concentrations uptake of compounds 1b and 1d did appear 
to be the more efficient than 1a and 1c. 
 
Circular Dichroism Analysis 
The M protein of GAS possesses an α-helical secondary structure, 
and this secondary structure is important for B cell recognition.[15] 
The CD spectra of the vaccine candidates 1a-d showed a varying 
degree of α-helicity. Each showed minima at approximately 205 
nm and 222 nm, which is characteristic of an α-helical structure 
(Figure 4). Vaccine candidate 1d displayed the most intense 
signal, and therefore, possessed the largest degree of α-helicity. 
The spectra of vaccine candidates 1b and 1c were comparable to 
that of 1d, while vaccine candidate 1a displayed the least intense 
signal, and thus, the lowest degree of α-helicity. 
Figure 4. CD spectrum of vaccine candidates 1a-d. 
ELISA Assay 
Immunological evaluation was performed on inbred C57BL/6 
mice. Mice (5 mice/group) were immunized subcutaneously at the 
tail base on day 0 with 30 µg of the vaccine candidates 1a-d, 
without administering an external adjuvant. The positive control 
group was treated with J8-CRM197/AAHSA, which is a 
formulation of the J8 peptide conjugated to the protein carrier 
Cross Reacting Material 197 (CRM197; a non-toxic analog of 
diphtheria toxoid), in amorphous aluminum hydroxyphosphate 
sulfate adjuvant (AAHSA). This formulation has recently been 
used by Caro-Aguilar et al., and was shown to be immunogenic 
in mice, as well as, in non-human primates.[37] The negative 
control group was administered sterile filtered PBS. Mice received 
two boosts of each immunogen at days 21 and 28 post-primary 
immunizations. Sera samples were collected prior to each boost 
and 11 days after the final boost, and the levels of J8-specific 
immunoglobulin G (IgG) were determined using ELISA. Three 
vaccine candidates 1b, 1c and 1d, and the positive control (J8-
Scheme 2. Synthesis of the glyco-lipopeptides 3a-d. 
 
Scheme 3. Synthesis of the glyco-lipopeptide 3d. 
 
Scheme 4. Preparation of vaccine candidates 1a-d using the CuAAC 
reaction. 
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CRM/alum) elicited significant J8-specific serum IgG titers at day 
39 versus PBS in different modes: 1b (p < 0.001); 1c (p < 0.001); 
1d (p < 0.001); and J8-CRM/alum (p < 0.0001) (Figure 5). 
Immunization with vaccine candidate 1a resulted in IgG antibody 
titers of approximately 1000 following the final boost. Vaccine 
candidates 1b, 1c and 1d elicited IgG titers of ~10,000 after a 
single dose (see Supporting Information), and subsequent boosts 
resulted in little or no increase in titers. 
Figure 5. J8-specific IgG titers elicited in response to vaccination of C57BL/6 
mice (n = 5/group) at day 39, serum IgG antibody titer (log 10). Mice received a 
primary subcutaneous immunization on day 0, followed by two boosts on days 
21 and 28. Samples were collected on day 39. Statistical analysis was 
performed by one-way ANOVA followed by the Tukey’s multiple comparisons 
test (*** = p < 0.001; **** = p < 0.0001). 
Conclusions 
Four self-adjuvanting vaccine candidates, were designed and 
synthesized using standard SPPS in 12-32% yields. Particle size 
of the vaccines was determined to be 9-11 nm. Dendritic cell and 
macrophage uptake studies indicated that the uptake of 1d and 
1b was more efficient compared to 1a and 1c. Analysis of vaccine 
candidate 1a by circular dichroism showed less intense minima at 
approximately 205 and 222 nm compared to vaccine candidates 
1b, 1c and 1d. This suggested that 1a displayed a less helical 
secondary structure compared to the other vaccine candidates. 
The immunogenicity of the vaccines was evaluated by in vivo 
assay performed in mice to measure the IgG titers. Vaccine 
candidates 1b, 1c and 1d showed significant induction of IgG 
when compared to PBS. 
Experimental Section 
Materials: Dimethylformamide (DMF), diethyl ether (Et2O), acetonitrile 
(CH3CN), trifluoroacetic acid (TFA), piperidine, and 2-(1H-benzotriazole-1-
yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HBTU) were 
obtained from Merck KgaA (Darmstadt, Germany). Dichloromethane 
(DCM) was purchased from Chem-Supply (Adelaide, Australia). 2-(1H-7-
azabenzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate 
(HATU) and all N-α-Fmoc protected amino acids were supplied by 
Mimotopes (Victoria, Australia). Rink amide 4-methylbenzhydrylamine 
(MBHA) resin was purchased from Novabiochem (Läufelfingen, 
Switzerland). All solvents and reagents were used as purchased, unless 
otherwise stated. 
 
Equipment: Microwave-assisted peptide couplings were performed using 
a CEM Discover Bio System manual peptide synthesiser (Matthews, USA). 
Mass spectra (MS) were obtained from a quatropol electrospray (Perkin 
Elmer Sciex API 3000 instrument) in the positive ion mode using Analyst 
1.4 software (Applied Biosystems/MDS Sciex, Toronto, Canada). 
Analytical RP-HPLC was performed on a Shimadzu (Kyoto, Japan) 
instrument (LC-20AT liquid chromatograph, CMB-20A communication bus 
module, SIL-20A HT auto sampler, CTO-20 column oven, SPD-M20A 
diode array detector, ELSD-LT II low temperature evaporative light 
scattering detector, LabSolutions software), with C18 or C4 Grace Vydac® 
(Columbia, Maryland, USA) columns (10 µm, 4.6 mm internal diameter x 
250 mm,) using a stated gradient of CH3CN/10% H2O/0.1% TFA (solvent 
B) and H2O/0.1% TFA (solvent A) with a 1 mL/min flow rate and detection 
at 214 nm. 
Semi-preparative RP-HPLC was performed using a Waters Delta 600 
system (Milford, Massachusetts, USA; Model 600 Controller, 490E UV 
Detector). Purifications were achieved using Vydac® C4 or C18 
preparative columns (10 µm, 10 mm internal diameter × 250 mm) using a 
stated gradient quoted as % solvent B at 4 mL/min flow rate, and detection 
at 214 nm. Fractions containing pure compound were pooled and 
lyophilized overnight. 
Preparative RP-HPLC was performed on a Shimadzu (Kyoto, Japan) 
instrument (LC-20AP liquid chromatograph, CMB-20A communication bus 
module, SPD-20 UV/Vis detector, FRC-10A fraction collector), with C18 or 
C4 Grace Vydac® (Columbia, Maryland, USA) columns (10 µm, 22 mm 
internal diameter x 250 mm) using a stated gradient quoted as % solvent 
B with a 20 mL/min flow rate and detection at 214 nm. 
Dendritic cells uptake assay was performed on BD LSR II flow cytometer. 
CD spectra were measured on a JASCO (Tokyo, Japan) J-710 
spectropolarimeter using a quartz cuvette of 1 mm path length at 23°C. 
Peptide Synthesis: Stepwise SPPS (manual and microwave-assisted) 
was performed using rink amide MBHA resin (substitution ratio: 0.79 
mmol/g) with standard Fmoc SPPS chemistry.  
Standard Fmoc SPPS Conditions: Fmoc-amino acids (4.2 equivalents 
(equiv.)) were pre-activated with HATU (0.4 M in DMF, 4 equiv.) and 
DIPEA (6.2 equiv.). Coupling cycles consisted of Fmoc deprotection with 
piperidine (20% in DMF, 2 x 15 min (manual) or 2 x 2 min, 70ºC 
(microwave)), DMF washing, followed by coupling with pre-activated 
Fmoc-amino acids (2 x 30 min (manual) or 2 x 5 min, 70ºC (microwave)). 
Acetylation was performed by treatment with a 1:1 mixture of acetic 
anhydride and DIPEA (5% in DMF) for 2 x 15 min (manual) or 2 x 2 min, 
70°C (microwave). After assembly of the required sequence, the peptidyl-
resin was washed with DMF and DCM, and dried under vacuum. Peptides 
were cleaved from the resin by stirring in a solution of TFA, 
triisopropylsilane (TIPS) and H2O (95:2.5:2.5) for 3 h. The resin was 
removed by filtration and the excess TFA was evaporated by a stream of 
N2. The peptides were precipitated from ice-cold Et2O, centrifuged, and the 
Et2O decanted. 
Glycopetide 2: Using standard microwave-assisted Fmoc SPPS, a linear 
peptide was prepared with the sequence KKFVAAWTLKAAKK. Fmoc-
Lys(ivDde)-OH was coupled using standard microwave-assisted Fmoc 
SPPS; although, the equivalents of the reagents were reduced: amino acid 
(2.5 equiv.), HATU (2.4 equiv.), DIPEA (4.6 equiv.). Following piperidine 
deprotection of the N terminus, the TPGlc (2,3,4,6-tetra-O-acetyl-1-O-(6-
methoxy-6-oxohexyl)-β-D-glucopyranose)12 carbohydrate building block 
(2.5 equiv. in 1 mL of DMF) and DIPEA (4.6 equiv.) were added to the resin 
with stirring. HBTU (2.4 equiv. in 1 mL of DMF) was added and the mixture 
was heated at 70°C in the microwave for 5 min. The process was repeated 
for a second time. The resin was washed with DMF and dilute hydrazine 
(7 mL, 2% in DMF) was added. The mixture was shaken for 1 h at room 
temperature, and the process repeated a further three times. Fmoc-
Lys(Boc)-OH was coupled to the deprotected side-chain amine using 
standard microwave-assisted SPPS. The peptidyl-resin was washed with 
DMF, DCM and dried under vacuum to give the resin-bound glycopeptide 
2, which was divided into four equal portions. 
Glyco-lipopetide 3a: A portion of resin-bound glycopeptide 2 (0.05 mmol) 
was allowed to swell in DMF for 1 h. Following Fmoc removal, the required 
10.1002/cbic.201600639ChemBioChem
This article is protected by copyright. All rights reserved.
FULL PAPER    
For internal use, please do not delete. Submitted_Manuscript 
 
 
 
 
lipidic adjuvanting sequence (Ac-C12-C12-G-C12-) was incorporated 
using standard manual Fmoc SPPS, unless otherwise stated. Dde-C12-
OH29 was coupled using standard coupling conditions and the Dde group 
was removed by treatment with hydrazine (2% in DMF, 3 x 20 min). The 
sequence was capped using standard acetylation conditions. Following 
cleavage from the resin and precipitation, the crude glyco-lipopeptide 3a 
was dissolved in a minimum volume of DMF, diluted with solvent A and B 
(1:1, 50 mL), and lyophilized. Glyco-lipopeptide 3a was used without 
purification; HPLC analysis (C4 column): tR=25.1 min (0% for 5 min, 0-
100% solvent B over 40 min); MS-ESI (m/z): [M+2H]2+ calcd 1483.4, found 
1484.4; [M+3H]3+ calcd 989.3, found 989.7; [M+4H]4+calcd 742.2, found 
742.9; molecular weight 2964.8 g/mol. 
Glyco-lipopetide 3b: A portion of resin-bound glycopeptide 2 (0.05 mmol) 
was allowed to swell in DMF for 1 h. Following Fmoc removal, the required 
lipidic adjuvanting sequence (Ac-C16-C16-S-S-) was incorporated using 
standard manual Fmoc SPPS, unless otherwise stated. Dde-C16-OH29 
was coupled using standard coupling conditions, and the Dde group was 
removed by treatment with hydrazine (2% in DMF, 3 x 20 min). The 
sequence was capped using standard acetylation conditions. Following 
cleavage from the resin and precipitation, the crude glyco-lipopeptide 3b 
was dissolved in a minimum volume of DMF, diluted with solvent A and B 
(1:1, 50 mL), and lyophilized. Glyco-lipopeptide 3b was used without 
purification; HPLC analysis (C4 column): tR=30.0 min (0% for 5 min, 0-
100% solvent B over 40 min); MS-ESI (m/z): [M+2H]2+ calcd 1499.4, found 
1499.6; [M+3H]3+ calcd 999.9, found 1000.4; [M+4H]4+ calcd 750.2, found 
750.1; [M+5H]5+ calcd 600.4, found 600.9; molecular weight 2996.8 g/mol. 
Glyco-lipopetide 3c: A portion of resin-bound glycopeptide 2 (0.05 mmol) 
was allowed to swell in DMF for 1 h. Following Fmoc removal, the required 
lipidic adjuvanting sequence (Ac-K(C12)-K(C12)-G-K(C12)-) was 
incorporated using standard microwave-assisted Fmoc SPPS, using 
Fmoc-Lys(C12)-OH (K(C12)) as the lipo-amino acid.12 The sequence was 
capped using standard acetylation conditions. Following cleavage from the 
resin and precipitation, the crude glyco-lipopeptide 3c was dissolved in a 
minimum volume of DMF, diluted with solvent A and B (1:1, 50 mL), and 
lyophilized. Glyco-lipopeptide 3c was used without purification; HPLC 
analysis (C4 column): tR = 28.4 min (0% for 5 min, 0-20% over 5 min, 20-
50% solvent B over 30 min); MS-ESI (m/z): [M+2H]2+ calcd 1653.2, found 
1654.0; [M+3H]3+ calcd 1102.4, found 1102.8; [M+4H]4+ calcd 827.1, found 
827.3; [M+5H]5+ calcd 661.9, found 662.4; molecular weight 3304.3 g/mol. 
Glyco-lipopetide 3d: A portion of resin-bound glycopeptide 1 (0.05 mmol) 
was allowed to swell in DMF for 1 h. Following Fmoc removal, two standard 
Fmoc-Ser(tBu)-OH amino acid residues were coupled using standard 
manual Fmoc SPPS. The non-standard amino acid Fmoc-Ser-OH was 
coupled by the addition of Fmoc-Ser-OH (4.2 equiv. in 1 mL of DMF) and 
DIPEA (6.2 equiv.) to the resin with stirring, followed by the addition of 
HBTU (4 equiv. in 1 mL of DMF). The mixture was rotated for 30 min, and 
the process was repeated. The resin was washed with DMF and the Fmoc 
group removed. DIC (156 µL, 1.0 mmol, 20 equiv.) was added to a solution 
of palmitic acid (0.513 g, 2.0 mmol, 40 equiv.) and DMAP (42.8 mg, 0.4 
mmol, 7 equiv.) in 5 mL of DMF, and the mixture was allowed to pre-
activate for 10 min. The pre-activated solution was added to the resin and 
the mixture was rotated at room temperature overnight (approx. 16 h). The 
resin was washed with DMF, DCM and dried. Following cleavage from the 
resin and precipitation, the crude glyco-lipopeptide 3d was dissolved in a 
minimum volume of DMF, diluted with solvent A and B (1:1, 50 mL), and 
lyophilized. Glyco-lipopeptide 3d was used without purification; HPLC 
analysis (C4 column): tR = 33.5 (0-50% over 10 min, 50-80% solvent B 
over 30 min); MS-ESI (m/z), [M + 2H]2+ calcd 1507.0, found 1506.1; [M + 
3H]3+ calcd 1005.0, found 1005.4; [M+4H]4+ calcd 754.0, found 754.5; 
molecular weight 3011.9 g/mol. 
General Procedure for Synthesis of Vaccine Candidates 1a-d: Crude 
glyco-lipopeptide 3a-d (2 mg) and N3-J812 (8 mol equiv.) were dissolved in 
DMF (2 mL) and copper wire (approx. 200 mg) was added. The mixture 
was stirred at 50°C under nitrogen until a blue/green color was 
distinguishable (approx. 1-2 h), at which point the reaction was cooled in 
a bath of dry ice. The copper wire was removed by filtration and the DMF 
filtrate was loaded directly onto a preparative C4 column (RP-HPLC). The 
vaccine candidate was eluted with a gradient of 0% for 28 min, 0-20% over 
2 min, and 20-60% solvent B over 60 min. 
Vaccine Candidate 1a: 1.3 mg, 12% purified yield; HPLC analysis (C4 
column): tR = 21.8 (0% for 2 min, 0-100% solvent B over 40 min); MS-ESI 
(m/z): [M+9H]9+ calcd 1825.9, found 1825.6; [M+10H]10+ calcd 1643.4, 
found 1643.8; [M+11H]11+ calcd 1494.1, found 1493.2; [M+12H]12+ calcd 
1369.7, found 1370.0; [M+13H]13+ calcd 1264.4, found 1264.6; [M+14H]14+ 
calcd 1174.1, found 1173.4; [M+15H]15+ calcd 1095.9, found 1096.1; 
[M+16H]16+ calcd 1027.5, found 1028.0; molecular weight 16424.0 g/mol. 
Vaccine Candidate 1b: 3.3 mg, 30% purified yield; HPLC analysis (C4 
column): tR = 22.6 (0% for 2 min, 0-100% solvent B over 40 min); MS-ESI 
(m/z): [M+9H]9+ calcd 1829.4, found 1830.2; [M+10H]10+ calcd 1646.6, 
found 1647.4; [M+11H]11+ calcd 1497.0, found 1497.3; [M+12H]12+ calcd 
1372.3, found 1372.6; [M+13H]13+ calcd 1266.8, found 1267.6; [M+14H]14+ 
calcd 1176.4, found 1176.7; [M+15H]15+ calcd 1098.1, found 1098.0; 
[M+16H]16+ calcd 1029.5, found 1029.6; molecular weight 16456.0 g/mol. 
Vaccine Candidate 1c: 3.3 mg, 31% purified yield; HPLC analysis (C4 
column): tR = 25.5 (0-20% for 5 min, 20-60% solvent B over 30 min); MS-
ESI (m/z): [M+6H]6+ calcd 2794.9, found 2794.7; [M+7H]7+ calcd 2395.8, 
found 2395.9; [M+8H]8+ calcd 2096.4, found 2097.0; [M+9H]9+ calcd 
1863.6, found 1864.2; [M+10H]10+ calcd 1677.4, found 1677.5; [M+11H]11+ 
calcd 1525.0, found 1525.7; [M+12H]12+ calcd 1398.0, found 1398.2; 
[M+13H]13+ calcd 1290.5, found 1290.9; [M+14H]14+ calcd 1198.4, found 
1198.8; [M+15H]15+ calcd 1118.5, found 1119.0; [M+16H]16+ calcd 1048.7, 
found 1048.9; molecular weight 16763.5 g/mol. 
Vaccine Candidate 1d: 2.1 mg, 19% purified yield; HPLC analysis (C4 
column): tR = 24.0 (0% for 2 min, 0-100% over 40 min); MS-ESI (m/z): [M 
+ 9H]9+ calcd 1831.1, found 1831.1; [M + 10H]10+ calcd 1648.1, found 
1648.8; [M + 11H]11+ calcd 1498.4, found 1498.9; [M + 12H]12+ calcd 
1373.6, found 1374.0; [M + 13H]13+ calcd 1268.0, found 1268.5; 
[M+14H]14+ calcd 1177.5, found 1177.8; [M+15H]15+ calcd 1099.1, found 
1099.4; [M+16H]16+ calcd 1030.4, found 1030.6; molecular weight 16471.1 
g/mol. 
Particle Size Analysis by DLS: The sample compound was prepared in 
PBS (60 µM) and transferred to a low-volume disposable plastic cuvette. 
Particle sizes were measured and analyzed with Zetasizer software on a 
Zetasizer Nano ZP instrument (Malvern Instruments, UK). Sample size 
measurements were carried out using the M3-PALS technique at 25ºC 
with a backscattering angle of 173º. Measurements were performed in 
triplicates and the average size by number was reported. 
Particle Size Analysis by TEM: The sample compound was dissolved in 
PBS (60 µM) and 50 µl was added to glow discharged carbon coated 200 
mesh grids for 3 min and excess liquid was wicked off with filter paper. 
Pictures were taken using a JEM-1010 transmission electron microscope 
(JEOL Ltd., Japan) operated at 80 kV. 
Dendritic Cell and Macrophage Uptake Assay: The uptake assays were 
performed according to previous studies.32, 33 Briefly, mouse spleens were 
passed through a 70 µm cell strainer, and the strainer was rinsed with PBS 
(40 mL). The cells were centrifuged (310 g, 10 min, 4°C) and the 
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supernatant was discarded. Erythrocyte lysis buffer (5 mL) (Sigma-Aldrich, 
Sydney, Australia) was added, and the cells were cooled to 0°C for 7 min. 
The cells were washed and centrifuged (as above) twice with PBS (2 x 35 
mL). The cells were resuspended in PBS (1 mL), plated on a 24 well round 
bottom plate (2 x 105/ well) in phenol free IMDM Glutamax medium (Gibco, 
Life Technologies, Melbourne, Australia) and incubated at 37°C for 4 h. 
The media was supplemented with 10% FBS, 50 μM 2-mercaptoethanol 
(Gibco, Life Technologies), 100 U/mL penicillin, and 100 μg/mL 
streptomycin (Gibco, Life Technologies). 
The vaccine candidates 1a-d (100 μL, 50 µM in PBS) were labelled with 
0.5 μL of Dil (1,1′-dioctadecyl-3,3,3′,3′-tetramethylindocarbocyanine 
perchlorate) (Vybrant, Life Technologies) by incubating at 4°C for 30 min. 
Cells were incubated with Dil-labelled compounds overnight at 37°C. The 
cells were removed from the plate and centrifuged (650 g, 5 min, 4°C). 
Cells were resuspended in 40 μL Fc receptor block (eBioscience, San 
Diego), incubated for 10 min at 4°C and centrifuged (as above). The cells 
were washed and centrifuged (as above) with FACS buffer (PBS, 0.02% 
sodium azide, 0.5% BSA) (3 x 50 µL). The cells were resuspended in 50 
μL of fixation buffer (eBioscience) and incubated for 20 min at room 
temperature. After fixation, the cells were washed and centrifuged (as 
above) with FACS buffer (3 x 100 μL), resuspended in 0.5 mL of FACS 
buffer, and analyzed using LSR II flow cytometry (BD Biosciences, San 
Jose, California). Dendritic cells and macrophages were also treated with 
PBS and Dextran-FITC (Chondrex, Inc., USA), and the fluorescent 
intensities were measured as negative and positive controls, respectively. 
The uptake was calculated as the percentage of cells double positive for 
conjugate (Dil) and CD11c (A660) or conjugate (Dil) and F4/80 (APC-Cy7) 
markers.  
Preparation of J8-CRM/alum Conjugate:[37] Purified CRM carrier protein 
was obtained from Merck Research Laboratories (Kenilworth, New Jersey), 
and activated for conjugation by the addition of maleimide groups to 
surface-accessible lysine residues using the heterobifunctional cross-
linking reagent succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-
carboxylate (SMCC, Thermo Fisher Scientific, Rockford, IL). Briefly, a 
concentrated stock of CRM in phosphate buffer was diluted in 20 mM 
HEPES, 0.15 M NaCl, 0.005 M EDTA, pH 7.3 to a total protein 
concentration of 1 mg/mL. 9 mg of SMCC (10-fold molar ratio to theoretical 
CRM lysine content) was dissolved in 1 mL of dry dimethyl sulfoxide 
(DMSO) and added to the CRM solution while it was being gently vortexed. 
The reaction mixture was incubated in the dark at room temperature for 3 
h. The sample was then reduced in volume to 5 mL using an Amicon Ultra 
centrifugal concentrator and desalted over a Hi Prep 26/10 desalting 
column (GE Healthcare Life Sciences, Parramatta, Australia) equilibrated 
in 20 mM HEPES, 0.15 M NaCl, 5 mM EDTA, pH 7.3. The amount of 
maleimide incorporated into the CRM was determined using a 5, 5'-
dithiobis-(2-nitrobenzoic acid) (DTNB)–based assay, which relies on the 
consumption of a fixed amount of N-acetyl cysteine from a standard 
solution. CRM total protein was determined by the bicinchoninic acid 
(BCA) protein assay. Conjugation of thiolated J8 peptide to maleimide-
activated CRM was performed at a 2:1 molar ratio of peptide thiol to CRM 
maleimide. The required amount of thiolated J8 peptide was weighed out 
and placed in a 20 mL glass vial, to which the activated CRM solution was 
added. The solution was mixed to ensure that the peptide was completely 
dissolved, and then incubated overnight at room temperature. The 
conjugate was purified of un-reacted peptide by size exclusion 
chromatography over a 2.5 by 45 cm Superdex 30 column equilibrated and 
run in 20 mM HEPES, 0.15 M NaCl, pH 7.3. The molar loading ratio of 
peptide to carrier was determined by quantitative amino acid analysis 
using least squares linear regression analysis and quantitation of unique 
amino acid residues generated during the conjugation reaction.[38] The 
adjuvants used for formulation was amorphous aluminum 
hydroxyphosphate sulfate (AAHSA; Merck Manufacturing Division, West 
Point, PA).  
Subcutaneous Immunization of Mice: Eight week-old female inbred 
C57BL/6 mice were used in this study (Animal Resource Centre, Western 
Australia). All animal protocols used were approved by the Animal Ethics 
Committee (The University of Queensland), in accordance with National 
Health and Medical Research Council (NHMRC) of Australia guidelines. 
Access to food and clean water was provided ad libitum.  
Cohorts of 5 mice were subcutaneously immunized at the base of the tail 
with 30 µg of vaccine candidates 1a-d dissolved in 50 µL of sterile PBS 
(Griffith University, Gold Coast, Australia). Similarly, a negative control 
group was administered 50 µL of PBS and a positive control received 30 
µg of J8-CRM197/AAHSA (total volume of 50 µL). Boosts of the same 
dosage were given on days 21 and 28 following primary immunization.  
Serum Collection: Serum was collected on days 20, 27 and 39. 10 µL of 
blood was collected from each mouse from the tail artery and diluted 10 
times with PBS. The serum was extracted by centrifugation and stored at 
-20oC.  
Determination of Antibody Titers: Detection of serum IgG antibodies 
against the J8 epitope was performed using ELISA, as previously 
reported.[39] Briefly, ELISA plates were coated with J8 (10 mg/mL) in 
carbonate coating buffer overnight at 4°C and blocked with 150 µL/well of 
5% skim milk for 90 min at 37°C. Serial dilutions of collected sera were 
prepared in 0.5% skim milk/PBS-Tween-20 buffer, starting at a 
concentration of 1:100, followed by 1:2 dilutions. Absorbance values were 
read at 450 nm in a microplate reader after the addition of the secondary 
antibody (peroxidase-conjugated antimouse IgG) and O-
phenylenediamine. The antibody titer was identified as the lowest dilution 
that gave an absorbance of more than 3 standard deviations above the 
mean absorbance of control wells (containing normal mouse serum). 
Statistical analysis (p < 0.05 = statistical significance) was performed with 
one-way ANOVA followed by Tukey’s post hoc test.  
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Graphics: 
 
Figure 1. Novel vaccine candidates 1a-d containing different lipidic adjuvanting moieties. 
 
 
 
 
 
Figure 2. Pam2Cys as it appears in the TLR2 active site[29] and the DiPalmitoyl Serine (DPS) adjuvant in a similar conformation. 
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Scheme 1. Synthesis of the resin bound glycopeptide 2. 
 
 
Scheme 2. Synthesis of the glyco-lipopeptides 3a-d. 
 
 
Scheme 3. Synthesis of the glyco-lipopeptide 3d. 
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Figure 3. Uptake of 1a-d by mouse splenocyte-derived DCs and macrophages presented as the percentage of cells positive for the test compound (labeled with 
Dil) and CD11c-A660 or F4/80-APC-Cy7. Dextran and Phosphate-Buffered Saline (PBS) were used for positive and negative controls, respectively. The bars 
represent the mean ± standard deviation of three experiments. 
 
 
Scheme 4. Preparation of vaccine candidates 1a-d using the CuAAC reaction. 
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Figure 4. CD spectrum of vaccine candidates 1a-d. 
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Figure 5. J8-specific IgG titers elicited in response to vaccination of C57BL/6 mice (n = 5/group) at day 39, serum IgG antibody titer (log 10). Mice received a primary 
subcutaneous immunization on day 0, followed by two boosts on days 21 and 28. Samples were collected on day 39. Statistical analysis was performed by one-
way ANOVA followed by the Tukey’s multiple comparisons test (*** = p < 0.001; **** = p < 0.0001). 
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